Reuters logo
Merck withdraws marketing application for Keytruda in Europe
October 27, 2017 / 8:46 PM / 24 days ago

Merck withdraws marketing application for Keytruda in Europe

(Reuters) - Merck & Co Inc said on Friday it had withdrawn its European application for Keytruda as a combination treatment for patients with an advanced stage of non-small cell lung cancer.

The company’s shares tumbled 8.9 percent to $56.50 in after-hours trading.

Earlier in the day, the U.S. drugmaker said quarterly sales of Keytruda exceeded $1 billion for the first time in the third quarter.

Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below